Oncology Ny
-
The contemporary management of breast cancer is a complex endeavor that requires a truly collaborative team approach, characterized by ongoing communication and active information-sharing among the multiple disciplines involved. Programs designed to provide comprehensive breast cancer management by a team of multidisciplinary specialists were introduced in the late 1970s and have been increasing slowly. ⋯ This interactive and dynamic forum has become integral to the interdisciplinary management of breast diseases and results in an increased level of communication between the participating health-care professionals and the patients they treat. Several professional organizations, most prominently the American Society of Breast Disease, promote and support an interdisciplinary approach to breast care.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Irinotecan in advanced lung cancer: focus on North American trials.
New agents with improved systemic activity are needed for the treatment of lung cancer. Irinotecan (Camptosar) is a promising agent in advanced non-small-cell (NSCLC) and small-cell lung cancer (SCLC). In a Japanese phase III trial of advanced NSCLC, irinotecan or irinotecan/cisplatin demonstrated a significant survival advantage compared to the standard of vindesine/cisplatin. ⋯ Current and planned trials in NSCLC with irinotecan in combination with gemcitabine (Gemzar), the taxanes, and other new agents, and thoracic radiotherapy should also provide useful clinical data. Moreover, trials in SCLC are investigating the rationale of combining irinotecan with a platinum agent as a component of chemoradiotherapy regimens. Promising data from these and other studies will further elucidate a role for irinotecan in the management of lung cancer.